参考文献/References:
[1] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature,1988,332(6163):411-415.
[2] Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological characterization of aprocitentan, a dual?endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental?hypertension[J]. J Pharmacol Exp Ther,2019,368(3):462-473.
[3] Planes N, Digman MA, Vanderheyden PPML, et al. Number and brightness analysis to study spatio-temporal distribution of the angiotensin II AT1?and the?endothelin-1?ETA?receptors: Influence of ligand binding[J]. Biochim Biophys Acta Gen Subj,2019, 1863(5):917-924.
[4] Huang G, Cheng P, Ding L, et al. Protective effect of Xin-Ji-Er-Kang on cardiovascular remodeling in high salt-induced hypertensive mice[J]. Exp Ther Med,2019,17(3):1551-1562 .
[5] Czopek A, Moorhouse R, Guyonnet L, et al. A novel role for myeloid endothelin-B receptors in hypertension[J].Eur Heart J,2019,40(9):768-784.
[6] Zhang Y, Zhao L, Li H, et al. Risk factors for hypertensive retinopathy in a Chinese population with?hypertension: The Beijing Eye study[J].Exp Ther Med,2019,17(1):453-458.
[7] Gradin K, Persson B. Endothelin A receptor?blockade improves endothelium-dependent relaxation in obese woman[J]. Physiol Res,2018,67(Supplementum 1):S167-S174.
[8] Alrashdi SF, Deliyanti D, Wilkinson-Berka JL. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats[J]. Exp Eye Res,2018,176:1-9.
[9] Ueno T, Hiwatashi S, Saka R, et al. Pulmonary arterial pressure management based on oral medicine for pediatric living donor liver transplant with portopulmonary?hypertension[J].Transplant Proc,2018,50(9):2614-2618.
[10] Oh DK, Song JM, Park DW, et al. The effect of a multidisciplinary team on the implementation rates of major diagnostic and therapeutic procedures of chronic thromboembolic pulmonary?hypertension[J].Heart Lung,2019,48(1):28-33.
[11] Panozzo CA, Woodworth TS, Welch EC, et a l. Early impact of the ICD-10-CM transition on selected health outcomes in 13 electronic health care databases in the United States[J]. Pharmacoepidemiol Drug Saf,2018,27(8):839-847.
[12] Burnier M. Update on endothelin receptor antagonists in?hypertension[J].Curr Hypertens Rep,2018,20(6):51.
[13] Dawson A, Reddecliffe S, Coghlan C, et al. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial?hypertension: an observational study[J]. Eur J Cardiovasc Nurs,2018,17(7):612-618.
[14] Gutiérrez A, Contreras C, Sánchez A, et al. Role of phosphatidylinositol 3-Kinase, mitogen-activated protein kinase, and protein kinase c in calcium signaling pathways linked to the α1-adrenoceptor in resistance Arteries[J]. Front Physiol,2019,10(3):55-68.
[15] Jin F. Analysis on mechanism of ATP-sensitive K+?channel opener natakalim improving congestive?heart failure?after myocardial infarction[J].Exp Ther Med,2016,12(6):3993-3997.
[16]Yuzugulen J, Douthwaite JA, Wood EG, et al. Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1[J].Sci Rep,2017,7(1):4956-4963.
[17] 王灵冰,滕欣越,张瑞,等.慢性心力衰竭与血管紧张素Ⅱ相关性分子机制研究进展[J].心血管病学进展, 2018,39(6):963-966.
[18] Skovsted GF, Kruse LS, Berchtold LA, et al. Myocardial ischemia-reperfusion enhances transcriptional expression of?endothelin-1?and vasoconstrictor ETB?receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat[J].PLoS One,2017,12(3): e0174119.
[19] Jacques D, D’Orléans-Juste P, Magder S, et al. Neuropeptide Y and its receptors in ventricular endocardial endothelial cells[J]. Can J Physiol Pharmacol,2017,95(10):1224-1229.
[20]Gergei I, Kr?mer BK, Scharnagl H, et al. Propeptide big-endothelin, N-terminal-pro brain natriuretic peptide and mortality. The Ludwigshafen risk and cardiovascular health (LURIC) study[J].Biomarkers,2017,22(4):315-320.
[21] Thirunavukkarasu C , Yang Y, Subbotin VM, et al.Endothelin receptor antagonist?TAK-044?arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats[J]. Gut, 2004,53(7):1010-1019.
[22]Jen HL, Yin WH, Chen JW, et al. Endothelin-1-induced cell hypertrophy in cardiomyocytes is improved by fenofibrate: possible roles of adiponectin[J].J Atheroscler Thromb,2017,24(5):508-517.
[23] Cassinotti LR, Guil MJ, Sch?ller MI, et al. Chronic blockade of brain?endothelin?receptor type-A (ETA) reduces blood pressure and prevents catecholaminergic overactivity in the right olfactory bulb of?DOCA-salt hypertensive rats[J].Int J Mol Sci,2018,19(3): 660-672.
[24]Seidlmayer LK, Kuhn J, Berbner A, et al.Inositol 1,4,5-trisphosphate-mediated sarcoplasmic reticulum-mitochondrial crosstalk influences adenosine triphosphate production via mitochondrial Ca2+ uptake through the mitochondrial ryanodine receptor in cardiac myocytes[J]. Cardiovasc Res,2016,112(1):491-501.
[25] Yuan W, Cheng G, Li B, et al. Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis[J]. Blood Press,2017,26(2):139-149.
[26] Raymond V, Steven VL, Griet G, et al. D eleting death and dialysis: conservative care of cardiovascular risk and kidney function loss in chronic kidney disease [J].Toxins,2018,10(6): 237-248.
[27] James AA, Richard JA, Christine EW,et al. Distortion of KB?estimates of endothelin-1 ETA?and ETB?receptor antagonists in pulmonary arteries: Possible role of an endothelin-1 clearance mechanism[J]. Pharmacol Res Perspect,2017,5(6): e00374.
[28] Schwabl P,Laleman W. Novel treatment options for portal hypertension[J].Gastroenterol Rep (Oxf),2017,5(2): 90-103.
[29] Hao W, Xuming S, Jeff C, et al. Cardiomyocyte-specific deletion of the G protein-coupled estrogen receptor (GPER) leads to left ventricular dysfunction and adverse remodeling: a sex-specific gene profiling analysis[J]. Biochim Biophys Acta,2017, 1863(8):1870-1882.
[30] Pavel J, Tom ás P. Macitentan?in pulmonary arterial hypertension:a focus on combination therapy in the SERAPHIN trial[J]. Am J Cardiovasc Drugs,2018,18(1):1-11.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(7):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(7):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(7):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[5]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[6]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[7]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[8]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(7):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[9]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(7):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[10]付士辉李玉龙骆雷鸣沈明志田进文邓珏琳.高血压基础研究现状与进展[J].心血管病学进展,2019,(9):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]
FU ShihuiLI YulongLUO LeimingSHEN MingzhiTIAN JinwenDENG Juelin.Status and Progress of Basic Researches about Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]